Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RAY1225 injection in overweight or obese adults
CTR20240363Phase 2Completed
- Sponsor
- Raynovent Biotech
- Start
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RAY1225 in obesity and Overweight (4 arms), sponsored by Raynovent Biotech. Primary endpoints: Treatment-emergent adverse events and Percent change in body weight from baseline. Started Feb 2024; status: completed.
02
Drugs
RAY1225
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20240363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240363.